
IGF-1 LR3 1mg Growth Factors
Long-acting IGF-1.
The long-acting form of IGF-1. An 83-amino-acid analogue whose N-terminal extension and Arg3 substitution reduce its affinity for binding proteins: where native IGF-1 is neutralised within minutes, this one stays active for hours. HPLC purity ≥98%, 1 mg vial. For research use only.
- In stock in France
Ordered with its water: shipped in a magnetic box
10% off every deliveryPause, skip or cancel in 1 clickNo commitment, no hidden fees
No automatic charge: pay for each delivery by card, in Bitcoin (an extra 5% off), or by bank transfer from €100
Your complete kit
The vial alone cannot be used as is. Add what you need to prepare it:
Frequently bought together
Research Use Only (RUO) · Prohibited for human or veterinary use.
Key facts
IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is a synthetic analogue of human IGF-1, with 83 amino acids against 70 for the native molecule. Two modifications set it apart: a 13-amino-acid N-terminal extension and the substitution of glutamic acid at position 3 with arginine (hence "R3").
Both changes target the same thingAffinity for the IGFBPs, the six binding proteins that sequester circulating IGF-1. Native IGF-1 is over 95% bound and its free plasma half-life is measured in minutes. The LR3 analogue binds them weakly and stays available far longer — that is the entire rationale for this research version.
In detail
This vial delivers 1 mg of IGF-1 LR3 at HPLC purity of at least 98%, lyophilised in type I borosilicate glass. For research use only.
Protocol and preparation
| Water added | Concentration | Reading marker |
|---|---|---|
| 1 ml | 1 mg/ml | 40 UI = 0,4 mg |
| 2 ml | 0,5 mg/ml | 40 UI = 0,2 mg |
The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.
Asepsis
Disinfect surfaces and stoppers (70% alcohol).
Solvent
Draw the required volume of bacteriostatic water.
Introduction
Inject gently against the vial wall (avoid direct jet on powder).
Solubilization
Roll the vial gently. Do not shake vigorously (degradation risk).
Solution storage Once reconstituted: 2-8°C (refrigerator).
Warning Theoretical tool for chemical handling. Does not constitute medical advice.
Open the dilution calculator- The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
- The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
- The vial carries no individual label. That is our standard packaging, not a downgraded vial.
- After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
- The parcel is plain. Nothing on the outside indicates the contents or the brand name.
What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.
Reconstitution. The 1 mg vial is reconstituted with 2 ml of bacteriostatic water, giving a 0.5 mg/ml solution, i.e. 500 mcg/ml. On a U-100 insulin syringe, 1 unit then equals 5 mcg, which makes small volumes readable without any calculation.
ProcedureLet the vial return to room temperature, disinfect the septum with 70% isopropyl alcohol, inject the water slowly along the inner wall and never directly onto the lyophilised cake, then gently roll the vial between your palms until dissolved. Never shake: the peptide's tertiary structure and its three disulfide bridges are sensitive to it.
On acetic acid. Part of the laboratory literature reconstitutes IGF-1 LR3 in dilute acetic acid (0.6%) for extended storage stability. We do not sell that solvent, and bacteriostatic water is adequate for ordinary use periods; it is a protocol choice, to be documented by the researcher.
Reported orders of magnitude. Research literature typically mentions quantities of 20 to 50 mcg per administration, i.e. 4 to 10 units on a U-100 syringe at this concentration. A 1 mg vial therefore represents 20 to 50 administrations depending on the scheme used. These figures are reported, not recommended.
Technical data
- Reconstitution
- 2 ml d'eau → 0,5 mg/ml. 1 UI = 5 mcg ; 4 UI = 20 mcg.
- Physical form
- Poudre lyophilisée blanche
- Recommended solubility
- Eau bactériostatique, NaCl 0.9%, acide acétique 0.1%
- Storage conditions
- Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
- Use
- Research reagent, in vitro only (RUO)
Storage & handling
Unreconstituted lyophilised vial: stable for several months between 2 and 8 °C, several years in a -20 °C freezer, protected from light. Ambient-temperature transport does not degrade it: the lyophilisate is designed to withstand far more than the duration of a shipment.
After reconstitution: refrigerated between 2 and 8 °C, protected from light. Bacteriostatic water, containing 0.9% benzyl alcohol, allows repeated draws over several weeks. Never freeze a reconstituted solution: a freeze-thaw cycle denatures the peptide even if the solution looks normal afterwards.
A light, uniform haze may appear after reconstitution; it is particles in suspension, a deposit that will not redissolve, or a yellow colour that justify discarding a vial.
Mechanism of action
IGF-1 acts on the IGF-1R receptor, a transmembrane tyrosine kinase of the insulin receptor family. Binding triggers receptor autophosphorylation and then two main cascades: the PI3K/Akt/mTOR pathway, associated in the literature with protein synthesis and cell survival, and the MAPK/ERK pathway, associated with proliferation.
What sets LR3 apart is not mechanistic but pharmacokinetic. The IGFBPs, particularly IGFBP-3, form a ternary complex with native IGF-1 that extends its circulating presence while making it unavailable. By reducing that binding, the LR3 analogue increases the free fraction — the amount of molecule actually able to reach the receptor.
Worth noting, as it is a common confusionReduced IGFBP affinity does not mean increased receptor affinity. LR3 binds IGF-1R with comparable, if slightly lower, affinity than native IGF-1.
Studies and references
IGF-1 is one of the best-characterised growth factors in the biomedical literature, with several decades of work on its role in growth, glucose metabolism and muscle physiology. Mecasermin, recombinant human IGF-1, holds marketing authorisation for severe primary IGF-1 deficiency, which gives the native molecule a solid pharmacological foundation.
The LR3 analogue, however, was developed and is still overwhelmingly used as a laboratory tool, notably in cell culture where it is widely employed as a medium supplement: its low IGFBP affinity is a direct advantage there, since the binding proteins present in serum would neutralise added native IGF-1.
There is no human clinical trial on IGF-1 LR3, and no authority has evaluated it for therapeutic use. Available data are preclinical, in vitro or animal, and that is the framework in which this product is sold.
Similar peptides
Against native IGF-1 (mecasermin). Same receptor, same cascade, but incomparable availability: native IGF-1 is over 95% sequestered by IGFBPs, LR3 largely escapes them. That is the only difference that matters in practice, and it is pharmacokinetic.
Against secretagogues (Ipamorelin, CJC-1295, Tesamorelin). The difference is one of level. Secretagogues act upstream: they stimulate the pituitary to release growth hormone, which then drives hepatic IGF-1 production. They therefore preserve physiological pulsatility and feedback loops. IGF-1 LR3 bypasses that chain and acts downstream, directly on the receptor. The two approaches are not interchangeable and are not documented in the same way.
Against MGF and PEG-MGF. MGF is a splice isoform of IGF-1, with a different E domain and local action; its pegylated form seeks to extend a naturally very short half-life. These are neighbouring but distinct molecules, with separate literatures.
Frequently asked questions
How much water to reconstitute the 1 mg vial?
Should I use acetic acid rather than bacteriostatic water?
What is the difference with classic IGF-1?
Are there clinical trials on IGF-1 LR3?
How many draws does a 1 mg vial represent?
Can it be combined with a secretagogue such as CJC-1295 or Ipamorelin?
Must the solution be perfectly clear?
The complete guideIGF-1 LR3: complete guide to structure, mechanisms and uses in peptide researchLong R3 IGF-1: modified variant, reduced IGFBP affinity, extraordinary half-life. Scientific decoding of the most studied peptide in RUO anabolic research.Read the guide 